Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UB 421

Drug Profile

UB 421

Alternative Names: dB4; dB4C7 mAb; mAb B4; UB421

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator United Biomedical
  • Developer United Biomedical; United BioPharma
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 05 Dec 2019 United BioPharma and National Institute of Allergy and Infectious Diseases enter into a clinical trial agreement for UB 421 in USA for HIV-1 infections
  • 02 Aug 2019 United BioPharma plans a phase II trial for HIV-1 infections (Adjunctive treatment, Combination therapy) (IV) in April 2020 (NCT04041362)
  • 21 May 2019 The US FDA approves IND application for a phase IIb/III trial in HIV-1 infection (Adjunctive therapy, Treatment-experienced) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top